Biotechnology from bench to business

• Follow GEN on:
• Login | Register | Subscribe

• ADME/Tox
• Automation
• Bioprocess Scale-Up
• Bioreactors
• Biosimilars
• Cell Culture
• Cell-Based Assays
• Contract Manufacturing
• Gene Therapy
• High-Throughput Screening
• Immunoassay
• Induced Pluripotent Stem Cells
• Informatics
• Liquid Handling
• Pharmacokinetics
• Protein Characterization
• Protein Detection
• Regenerative Medicine
• RNAi/siRNA
• Stem Cells
• Western Blot

• GEN Articles

• More »

• BioPerspectives: Avoiding “Incidental” Damages
  Presidential panel, ACMG, and experts struggle with what patients should learn, and how.
• Feature Articles: Nucleic Acid Sample Preparation in MDx
  
• Legal Affairs: Diagnostic Tests and Patent Eligibility
  Will the Federal Circuit’s Negative Treatment Chill Innovation?
• BioMarket Trends: IVD Market Moving Rapidly on an Upward Trajectory
  Sales within Eight Major Segments Will Yield Over $50 Billion by 2014
• Wall Street BioBeat: Companion Dx and Personalized Medicine
  

• Insight & Intelligence™

• More »

• 7 Biotech Trends for the Coming Year
  January 7, 2013
  What does 2013 hold for the industry?
• LAVAgel for Protein Diagnostics
  September 10, 2012
  Researchers introduce a microfluidic, single-channel, multistage immunoblotting strategy toward scalable protein isoform analysis.
• Blood Flow as Diagnostic Marker
  August 17, 2012
  Jamming, or vaso-occlusion, could be used to distinguish sickle cell disease patients with poor outcomes from those with good outcomes.
• Harvard Professor Rides Genomics' Third Wave
  July 3, 2012
  New Firm Aims to Advance Personalized Medicine through Precision Diagnostics
• This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
  June 1, 2012
  Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.

• GEN News Highlights

• More »

• Gates Foundation, EC Agree to Fight Poverty-Related Diseases
  
• Triple Threat: New Dx Firm Forged from Three-Company Merger
  
• Tracking White Blood Cell Counts at Home
  
• Lpath, Provista to Develop Lipid-Based Cancer Dx
  
• AMA Enters Diagnostic Fray
  

• Video Channel

• More »

• James M. Wilson, M.D., Ph.D., on Biotech's Past & Future
  
• Stelios Papadopoulos, Ph.D., Comments on Biotech & Society
  

• BLOG Biotech

• More »

• Preliminary Thoughts on the Implications of Prometheus v. Mayo for Biotechnology
  
• Personalized Medicine Takes a Hit
  
• Bring a Friend: Cancer Companion Diagnostics Become Popular
  
• Drawing Out Cancer With Biomarkers
  

• New Products

• More »

GE Healthcare Life Sciences Nitrocellulose Membranes The Whatman™ FF High Performance (HP) membrane is a diagnostic membrane that enables line separation and reproducible results for the detection of target molecules in liquids such as water, urine, blood, and saliva. The target molecules may include

• Webinars

• More »

• Supplier Webinars: Personalized Medicine Through Integrated Next Generation Sequencing Webinar
  

• Best Science Apps

• More »

• epTools